DK1453512T3 - Acetylenderivater med mGluR5 antagonistisk virkning - Google Patents

Acetylenderivater med mGluR5 antagonistisk virkning

Info

Publication number: DK1453512T3
Authority: DK; Denmark
Prior art keywords: antagonistic effect; acetylene derivatives; mglur5; mglur5 antagonistic; acetylene
Prior art date: 2001-12-04

Application number

DK02792867T

Other languages

English (en)

Inventor

Fabrizio Gasparini

Yves Auberson

Silvio Ofner

Kaspar Zimmermann

Terance W Hart

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-04

Filing date

2002-12-03

Publication date

2006-08-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9926969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1453512(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-12-03 Application filed by Novartis Ag filed Critical Novartis Ag

2006-08-28 Application granted granted Critical

2006-08-28 Publication of DK1453512T3 publication Critical patent/DK1453512T3/da

Links

102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 title 1
108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 title 1
150000000475 acetylene derivatives Chemical class 0.000 title 1
230000003042 antagnostic effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/23—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Indole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

DK02792867T 2001-12-04 2002-12-03 Acetylenderivater med mGluR5 antagonistisk virkning DK1453512T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0128996.6A GB0128996D0 (en)	2001-12-04	2001-12-04	Organic compounds

Publications (1)

Publication Number	Publication Date
DK1453512T3 true DK1453512T3 (da)	2006-08-28

Family

ID=9926969

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02792867T DK1453512T3 (da)	2001-12-04	2002-12-03	Acetylenderivater med mGluR5 antagonistisk virkning

Country Status (31)

Country	Link
US (4)	US7348353B2 (da)
EP (1)	EP1453512B8 (da)
JP (2)	JP4176020B2 (da)
KR (2)	KR100959204B1 (da)
CN (2)	CN101366714B (da)
AR (2)	AR037682A1 (da)
AT (1)	ATE327755T1 (da)
AU (1)	AU2002358585B2 (da)
BR (1)	BR0214666A (da)
CA (1)	CA2466560C (da)
CO (1)	CO5590929A2 (da)
CY (1)	CY1105460T1 (da)
DE (1)	DE60211944T2 (da)
DK (1)	DK1453512T3 (da)
EC (1)	ECSP045139A (da)
EG (1)	EG24936A (da)
ES (1)	ES2263842T3 (da)
GB (1)	GB0128996D0 (da)
HU (1)	HU229429B1 (da)
IL (1)	IL161990A0 (da)
MX (1)	MXPA04005456A (da)
MY (1)	MY137774A (da)
NO (1)	NO327005B1 (da)
NZ (1)	NZ533266A (da)
PE (1)	PE20030640A1 (da)
PL (1)	PL212996B1 (da)
PT (1)	PT1453512E (da)
RU (1)	RU2341515C2 (da)
TW (1)	TWI328578B (da)
WO (1)	WO2003047581A1 (da)
ZA (1)	ZA200403713B (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0128996D0 (en) *	2001-12-04	2002-01-23	Novartis Ag	Organic compounds
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
GB0325956D0 (en) *	2003-11-06	2003-12-10	Addex Pharmaceuticals Sa	Novel compounds
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
GB0503646D0 (en) *	2005-02-22	2005-03-30	Novartis Ag	Organic compounds
GB0508318D0 (en) *	2005-04-25	2005-06-01	Novartis Ag	Organic compounds
GB0508319D0 (en) *	2005-04-25	2005-06-01	Novartis Ag	Organic compounds
GB0508314D0 (en) *	2005-04-25	2005-06-01	Novartis Ag	Organic compounds
GB0514296D0 (en) *	2005-07-12	2005-08-17	Novartis Ag	Organic compounds
EP2272509A1 (en)	2006-09-11	2011-01-12	Novartis AG	New Uses of metabotropic glutamate receptors
WO2008151257A2 (en)	2007-06-04	2008-12-11	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2010003913A (es) *	2007-10-12	2010-04-27	Novartis Ag	Moduladores de los receptores de glutamato metabotropicos para el tratamiento de enfermedades de parkinson.
AU2012254934B2 (en) *	2007-10-12	2013-10-17	Novartis Ag	Metabotropic glutamate receptor modulators for the treatment of Parkinson's disease
ES2627848T3 (es)	2008-06-04	2017-07-31	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2010000763A2 (en) *	2008-06-30	2010-01-07	Novartis Ag	Combination products
NZ590753A (en) *	2008-08-12	2012-06-29	Novartis Ag	Processes for the preparation of 4-oxo-octahydro-indole-1-carbocylic acid methyl ester and derivatives thereof
US8334287B2 (en)	2009-07-17	2012-12-18	Hoffmann-La Roche Inc.	Imidazoles
EP2456438A2 (en)	2009-07-23	2012-05-30	Novartis AG	Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
TWI558398B (zh)	2009-09-22	2016-11-21	諾華公司	菸鹼乙醯膽鹼受體α７活化劑之用途
WO2011048150A1 (en)	2009-10-20	2011-04-28	Novartis Ag	Use of 1h-quinazoline-2,4-diones
WO2011137206A1 (en) *	2010-04-30	2011-11-03	Novartis Ag	Predictive markers useful in the treatment of fragile x syndrome (fxs)
CA2800970A1 (en)	2010-06-24	2011-12-29	Novartis Ag	Use of 1h-quinazoline-2,4-diones
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
US20130274294A1 (en) *	2010-12-20	2013-10-17	David Carcache	4-(Hetero)Aryl-Ethynyl-Octahydro-Indole-1-Esters
EP2668159A1 (en)	2011-01-24	2013-12-04	Novartis AG	4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
US20140171448A1 (en)	2011-01-27	2014-06-19	Novartis Ag	Use of nicotinic acetylcholine receptor alpha 7 activators
EA201391348A8 (ru)	2011-03-18	2014-11-28	Новартис Аг	КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА
CA2846503A1 (en)	2011-09-07	2013-03-14	Novartis Ag	Use of 1h-quinazoline-2,4-diones for use in the prevention or treatment of photosensitive epilepsy
WO2013131981A1 (en)	2012-03-08	2013-09-12	Novartis Ag	Predictive markers useful in the diagnosis and treatment of fragile x syndrome (fxs)
GB201215033D0 (en)	2012-08-23	2012-10-10	Novartis Ag	Diazepinone derivatives
MX379289B (es)	2013-01-15	2025-03-10	Novartis Ag	Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
JP6137336B2 (ja)	2013-01-15	2017-05-31	ノバルティスアーゲー	ナルコレプシーの処置のためのアルファ７ニコチン性受容体アゴニストの使用
EP2968439A2 (en)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en)	2013-03-15	2017-07-18	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
PL3004138T3 (pl)	2013-06-05	2024-07-29	Bausch Health Ireland Limited	Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
SG11201509178TA (en) *	2013-06-12	2015-12-30	Novartis Ag	Modified release formulation
GB201312800D0 (en)	2013-07-17	2013-08-28	Heptares Therapeutics Ltd	mGlu5 modulators
CN105669686B (zh) *	2014-11-19	2018-08-03	上海合全药业股份有限公司	一种6-(叔丁氧羰基)八氢呋喃[2,3-c]吡啶-4-羧酸的合成方法
AU2018310882C1 (en)	2017-07-31	2021-12-09	Novartis Ag	Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use
KR20200035035A (ko)	2017-07-31	2020-04-01	노파르티스 아게	코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
KR20210120011A (ko) *	2019-01-29	2021-10-06	노파르티스 아게	오피오이드 진통제 내약성을 치료하기 위한 mglur5 길항제의 용도
EP4007575B1 (en) *	2019-11-05	2023-09-27	Claes THULIN	4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4h-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of stress
JP7620694B2 (ja) *	2020-07-17	2025-01-23	ノバルティスアーゲー	オピオイド使用の低減用医薬品及びオピオイド禁断の促進用医薬品
WO2022123482A1 (en)	2020-12-11	2022-06-16	Novartis Ag	Use of mglur5 antagonists for treating amphetamine addiction
CA3204360A1 (en)	2020-12-14	2022-06-23	Novartis Ag	Use of mglur5 antagonists for treating gambling disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2741009A1 (de) *	1976-09-22	1978-03-23	Sandoz Ag	4-styryl-4-indolinol-derivate, ihre verwendung und herstellung
DE2802833A1 (de)	1978-01-23	1979-07-26	Sandoz Ag	4-styryl-4-indolinol-derivate, ihre verwendung und herstellung
US5264456A (en)	1989-12-29	1993-11-23	Allergan, Inc.	Acetylenes disubstituted with a furyl group and a substituted phenyl group having retinoid like activity
US5284957A (en) *	1992-09-03	1994-02-08	Eli Lilly And Company	Excitatory amino acid receptor antagonists
US5593994A (en)	1994-09-29	1997-01-14	The Dupont Merck Pharmaceutical Company	Prostaglandin synthase inhibitors
CA2502764A1 (en)	1995-08-22	1997-03-06	Japan Tobacco Inc.	Amide compounds
CA2258728C (en)	1996-06-19	2011-09-27	Rhone Poulenc Rorer Limited	Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
TW544448B (en) *	1997-07-11	2003-08-01	Novartis Ag	Pyridine derivatives
AU4059199A (en)	1998-06-04	1999-12-20	Ihara Chemical Industry Co. Ltd.	Phenylacetylene derivatives and agricultural/horticultural bactericides
ID29095A (id)	1998-10-02	2001-07-26	Novartis Ag Cs	Antagonis mglur5 untuk pengobatan rasa sakit dan kegelisahan
DZ3209A1 (fr)	1999-07-06	2001-01-11	Lilly Co Eli	Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.
GB0007108D0 (en)	2000-03-23	2000-05-17	Novartis Ag	Organic compounds
CA2426430C (en)	2000-10-20	2014-10-07	Biocryst Pharmaceuticals, Inc.	Biaryl compounds as serine protease inhibitors
NZ525917A (en) *	2000-12-04	2005-11-25	F	Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists and their use in treating mGLuR5 receptor mediated disorders
GB0103045D0 (en)	2001-02-07	2001-03-21	Novartis Ag	Organic Compounds
US7138404B2 (en)	2001-05-23	2006-11-21	Hoffmann-La Roche Inc.	4-aminopyrimidine derivatives
TW200303309A (en)	2001-12-04	2003-09-01	Bristol Myers Squibb Co	Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors
PL370766A1 (en)	2001-12-04	2005-05-30	F.Hoffmann-La Roche Ag	Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
GB0128996D0 (en)	2001-12-04	2002-01-23	Novartis Ag	Organic compounds

2001
- 2001-12-04 GB GBGB0128996.6A patent/GB0128996D0/en not_active Ceased
2002
- 2002-12-01 EG EG2002121297A patent/EG24936A/xx active
- 2002-12-02 AR ARP020104641A patent/AR037682A1/es not_active Application Discontinuation
- 2002-12-02 PE PE2002001157A patent/PE20030640A1/es not_active Application Discontinuation
- 2002-12-02 TW TW091134933A patent/TWI328578B/zh not_active IP Right Cessation
- 2002-12-03 KR KR1020047008477A patent/KR100959204B1/ko not_active Expired - Fee Related
- 2002-12-03 RU RU2004120781/04A patent/RU2341515C2/ru not_active IP Right Cessation
- 2002-12-03 CN CN200810166366.0A patent/CN101366714B/zh not_active Expired - Lifetime
- 2002-12-03 NZ NZ533266A patent/NZ533266A/en not_active IP Right Cessation
- 2002-12-03 DK DK02792867T patent/DK1453512T3/da active
- 2002-12-03 HU HU0402191A patent/HU229429B1/hu unknown
- 2002-12-03 MY MYPI20024525A patent/MY137774A/en unknown
- 2002-12-03 JP JP2003548836A patent/JP4176020B2/ja not_active Expired - Lifetime
- 2002-12-03 EP EP02792867A patent/EP1453512B8/en not_active Expired - Lifetime
- 2002-12-03 KR KR1020107002745A patent/KR100980901B1/ko not_active Expired - Fee Related
- 2002-12-03 WO PCT/EP2002/013670 patent/WO2003047581A1/en not_active Ceased
- 2002-12-03 PL PL368739A patent/PL212996B1/pl unknown
- 2002-12-03 US US10/497,363 patent/US7348353B2/en not_active Expired - Lifetime
- 2002-12-03 AT AT02792867T patent/ATE327755T1/de active
- 2002-12-03 ES ES02792867T patent/ES2263842T3/es not_active Expired - Lifetime
- 2002-12-03 DE DE60211944T patent/DE60211944T2/de not_active Expired - Lifetime
- 2002-12-03 AU AU2002358585A patent/AU2002358585B2/en not_active Ceased
- 2002-12-03 MX MXPA04005456A patent/MXPA04005456A/es active IP Right Grant
- 2002-12-03 IL IL16199002A patent/IL161990A0/xx not_active IP Right Cessation
- 2002-12-03 BR BR0214666-5A patent/BR0214666A/pt not_active Application Discontinuation
- 2002-12-03 CA CA2466560A patent/CA2466560C/en not_active Expired - Fee Related
- 2002-12-03 PT PT02792867T patent/PT1453512E/pt unknown
- 2002-12-03 CN CNB028232968A patent/CN100430059C/zh not_active Expired - Lifetime
2004
- 2004-05-14 ZA ZA2004/03713A patent/ZA200403713B/en unknown
- 2004-06-04 EC EC2004005139A patent/ECSP045139A/es unknown
- 2004-06-07 CO CO04053105A patent/CO5590929A2/es active IP Right Grant
- 2004-06-25 NO NO20042673A patent/NO327005B1/no not_active IP Right Cessation
2006
- 2006-08-03 CY CY20061101091T patent/CY1105460T1/el unknown
2008
- 2008-02-29 US US12/040,081 patent/US20080146647A1/en not_active Abandoned
- 2008-07-09 JP JP2008179005A patent/JP5036648B2/ja not_active Expired - Lifetime
2011
- 2011-09-22 US US13/239,467 patent/US8536229B2/en not_active Expired - Lifetime
2012
- 2012-11-20 AR ARP120104356A patent/AR088921A2/es not_active Application Discontinuation
2013
- 2013-08-15 US US13/967,719 patent/US20130331568A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HUP0402191A2 (hu)	2005-02-28
PT1453512E (pt)	2006-10-31
KR100959204B1 (ko)	2010-05-19
ATE327755T1 (de)	2006-06-15
CN101366714A (zh)	2009-02-18
BR0214666A (pt)	2004-11-03
DE60211944D1 (de)	2006-07-06
CN1592623A (zh)	2005-03-09
HUP0402191A3 (en)	2010-03-29
AR037682A1 (es)	2004-12-01
US20130331568A1 (en)	2013-12-12
KR20100020044A (ko)	2010-02-19
CY1105460T1 (el)	2010-04-28
ES2263842T3 (es)	2006-12-16
ZA200403713B (en)	2005-10-26
GB0128996D0 (en)	2002-01-23
NO20042673L (no)	2004-06-25
US20120010263A1 (en)	2012-01-12
ECSP045139A (es)	2004-07-23
CN100430059C (zh)	2008-11-05
NO327005B1 (no)	2009-04-06
NZ533266A (en)	2005-02-25
US20080146647A1 (en)	2008-06-19
IL161990A0 (en)	2005-11-20
HU229429B1 (en)	2013-12-30
AR088921A2 (es)	2014-07-16
CN101366714B (zh)	2014-09-17
CA2466560C (en)	2010-07-27
EP1453512B8 (en)	2006-07-19
JP2005514381A (ja)	2005-05-19
RU2004120781A (ru)	2006-01-10
TWI328578B (en)	2010-08-11
US7348353B2 (en)	2008-03-25
EP1453512A1 (en)	2004-09-08
PE20030640A1 (es)	2003-09-12
WO2003047581A1 (en)	2003-06-12
AU2002358585A1 (en)	2003-06-17
CO5590929A2 (es)	2005-12-30
MXPA04005456A (es)	2004-10-11
JP2008303226A (ja)	2008-12-18
CA2466560A1 (en)	2003-06-12
EG24936A (en)	2011-01-11
KR100980901B1 (ko)	2010-09-07
JP5036648B2 (ja)	2012-09-26
US20050065191A1 (en)	2005-03-24
HK1071510A1 (en)	2005-07-22
JP4176020B2 (ja)	2008-11-05
EP1453512B1 (en)	2006-05-31
MY137774A (en)	2009-03-31
PL212996B1 (pl)	2012-12-31
PL368739A1 (en)	2005-04-04
DE60211944T2 (de)	2007-05-16
AU2002358585B2 (en)	2006-01-19
TW200304910A (en)	2003-10-16
RU2341515C2 (ru)	2008-12-20
KR20050044657A (ko)	2005-05-12
US8536229B2 (en)	2013-09-17

Publication	Publication Date	Title
HUS1500055I1 (hu)	2016-03-29	HIV-gátló pirimidinszármazékok
DE50210090D1 (de)	2007-06-14	Substituierte phenylderivate
ATE319451T1 (de)	2006-03-15	Tetrahydrochinolin-derivate
NO20034439L (no)	2003-12-02	Benzamidinderivater
DK1556385T3 (da)	2010-06-14	Heterocyclocarboxamid-derivater
DK1551802T3 (da)	2010-03-15	Indol-3-svovlderivater
ATE467631T1 (de)	2010-05-15	Chinuclidinamidderivate
ATE438644T1 (de)	2009-08-15	Chinazolinderivate
IS7720A (is)	2005-03-01	Píperidín-N-oxíð-afleiður
DK2248807T3 (da)	2013-08-26	N-Phenyl-2-pyrimidinaminderivater
ATE312827T1 (de)	2005-12-15	3-substituierte-4-pyrimidonderivate
NO20042673L (no)	2004-06-25	Acetylenderivaer som har mGluR5 antagonistisk aktivitet
ATE430129T1 (de)	2009-05-15	Substituierte thioacetamide
ATE335729T1 (de)	2006-09-15	3h-chinazoline -4-on derivaten
ATE423771T1 (de)	2009-03-15	Tetrahydrochinolinderivate
DE60223031D1 (de)	2007-11-29	Arylpiperazin gebundene tetrahydroindolonderivate
DE60212694D1 (de)	2006-08-03	Benzothiazolderivaten
NO20042980L (no)	2004-07-14	3,4-dihydro-1H-isokinolin-2-yl-derivater
ATE346045T1 (de)	2006-12-15	Heteroaryl-substituierte aminocyclohexan-derivate
DE50306277D1 (de)	2007-02-22	4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
ATE382601T1 (de)	2008-01-15	Substituierte 4-aminocyclohexanolderivate
PL357094A1 (pl)	2004-07-12	Heterocykliczne pochodne amidów
DE60202381D1 (de)	2005-01-27	Paroxetin-n-formyl-derivate
IS7906A (is)	2005-06-22	Afleiður própargýl-tríflúorómetoxý-amínó-benzóþíazóls
ATE360010T1 (de)	2007-05-15	Heterocyclische retioidverbindungen